Ginkgo Bioworks is involved in synthetic biology, providing data-driven R&D services for various industries including agriculture and biopharma. Self-described as the Organism Company.

Ginkgo Bioworks

Grow by Ginkgo

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to ensure that DEI is in our DNA, continuing to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.

Synlogic

Empede Capital

General Atlantic

Y Combinator

Bill Gates

T. Rowe Price

Viking Global Investors

Cascade Investment

Illumina

Ginkgo Bioworks, Inc.

This week on Foundry Theory! What is it about biotech R&D that makes collaboration challenging? How can we make it easier?
https://hubs.la/Q02NTygX0

We're excited to welcome Patrick Boyle as an Advisor at SIC. Patrick is currently Ginkgo Bioworks, Inc.'s Chief Scientific Officer, having been at Ginkgo from the earliest days as one of the first full time scientist hires at the company in 2012. As a pioneer in synthetic and computational biology, Patrick brings unparalleled expertise to our extended network. His experience in developing Ginkgo’s codebase and driving customer-focused business development is a powerful addition to our firm’s toolkit. Welcome Patrick!

https://lnkd.in/eZjsX4ZQ

I tried to go a bit sassy and provocative in this week's video, asking "which type of nerds are the coolest?"

My professional opinion: it's the bio nerds

We're #hiring a new Director, Infrastructure Enablement in United States. Apply today or share this post with your network.

Ginkgo is pleased to announce Max Breet, Director of Business Development EMEA, will be joined by other industry experts at this year's upcoming GLOBSEC Forum to discuss the growing need for robust biosecurity infrastructure and what it will take to get us there!

#GLOBSEC2024 #GLOBSECPRAGUE

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Analytics

Content Delivery Network

WordPress

Founder

Austin Che

Sales and Support

Ena Cratsenburg

Helen Maimaris

Reshma Shetty

SVP, Corporate Development

Anna Wagner

Senior Vice President Biopharma Manufacturing & Life Sciences Tools (DNA: NYSE)

Behzad Mahdavi

VP/Head of Infrastructure Operations

Greg Loconte

Vice President of Business Development

Jess Leber

Vice President, Continuous Improvement & Industrial Engineering

Kevin Wright

Vice President of Commercial Operations

Laura Bronner

Reshma Kewalramani

Aaron Schwartz

Tom Knight

Co-founder

Jason Kelly

CEO & Co-Founder

Barry Canton

Co-Founder

VP Commercial

Steven Coen

Chief Accounting Officer

Han Xu

Senior Product Designer

Herbert Ryan

Head of Fermentation Automation

Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.

Greater Boston Area Companies With More Than 500 Employees

New England Companies With Less Than $500M in Revenue (Top 10K)

Companies With Less Than $500M in Revenue (Top 10K)

Companies With More Than 50 Employees (Top 10K)

Ginkgo Bioworks is a biotechnology firm. It is a developer of biological engineering products and custom microbes across multiple markets. It designs, engineer, develops, tests, and licenses organisms. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. It also provides probiotic bacteria to protect the body from dangerous infections, and it generates libraries of molecules. It serves cultured ingredients, carbon mitigation, probiotics, and natural product discovery markets.

Bill & Melinda Gates Foundation

Grant - Ginkgo Bioworks

Centers for Disease Control and Prevention

Agriculture and Food Research Initiative

Post-IPO Equity - Ginkgo Bioworks

Series B - Ginkgo Bioworks

Series F - Ginkgo Bioworks

Series E - Ginkgo Bioworks

Series D - Ginkgo Bioworks

Series C - Ginkgo Bioworks

The Ferment Fund

Computer and Software Services and Scientific Services

Boston

Massachusetts

United States

North America

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

Medication Management System Market Size, Share, Revenue, Trends, and Drivers For 2024-2033

Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation

Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing

Ginkgo Bioworks lands in Brazil through partnerships

Context makes a T cell engager deal; Ginkgo Bioworks backers have a new SPAC

Ginkgo Bioworks rises 18.1%

Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development

2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock

Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?

India

Asia

Switzerland

Europe

France

Canada

HTML5

Gravity Forms

Wordpress

DigiCert

Vimeo

Cloudflare CDN

Google Drive

jQuery

Google Fonts

Google Compute Engine

Ginkgo Bioworks owns Arcaea

Allozymes is a competitor of Ginkgo Bioworks in the biotechnology industry, focusing on cell programming and providing similar services.

Allozymes

Algal Bio is a competitor of Ginkgo Bioworks in the biotechnology sector, specializing in cell programming and offering comparable services.

Algal Bio

EnginZyme is a direct competitor of Ginkgo Bioworks, providing cell programming services and solutions across diverse markets.

EnginZyme

Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, specializing in using genetic engineering to produce bacteria with industrial applications for other biotech companies. The company aims to leverage biology as an advanced manufacturing technology to program cells for various applications in therapeutics, agriculture, nutrition, wellness, and more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

news impact assignment basic	general	Oct 2, 2024 10:49 AM	2f42de83
public peers	general	Oct 2, 2024 10:49 AM	a8c1086d
news daily refresh	general	Oct 2, 2024 10:49 AM	2e34b95c
news processing daily refresh	general	Oct 2, 2024 10:49 AM	32766900
news impact assignment daily	general	Oct 2, 2024 10:49 AM	1eab5c18
news processing basic	general	Oct 2, 2024 10:49 AM	dbf61eaf
company summary	general	Oct 2, 2024 10:49 AM	a8dc7527
signals	general	Oct 2, 2024 10:49 AM	e0e4b8b9
crunchbase trigger	general	Nov 27, 2024 12:50 PM	b89c36a7
crunchbase profile	general	Nov 27, 2024 1:29 PM	ef90df92
li profile	general	Oct 2, 2024 10:49 AM	8c37d04d
translate crunchbase fundingrounds	general	Nov 27, 2024 3:46 PM	3cda612b
peers	general	Oct 2, 2024 10:49 AM	ba7006b7
news basic	general	Oct 2, 2024 10:49 AM	e8657e37
bundesanzeiger	filings	Oct 2, 2024 10:49 AM	06b238d5
financials download nd	financials
private financials	financials

COM:GINKGOBIOWORKS

Ginkgo Bioworks

Last Close

6.59

22/11 21:00

Market Cap

725.64M

Beta: -

Volume Today

129

Avg: -